



WILLIAMS, MORGAN & AMERSON, P.C.

7676 HILLMONT, SUITE 250, HOUSTON, TX 77040  
(713) 934-7000 Fax (713) 934-7011

Danny L. Williams  
Terry D. Morgan  
J. Mike Amerson  
Kenneth D. Goodman  
Jeffrey A. Pyle  
Jaison C. John  
Randall C. Furlong, Ph.D.

RECEIVED

MAR 26 2001

TECH CENTER 1600/2900


1642  
Scott F. Diring\*  
George J. Oehling\*  
Shelley P.M. Fussey, Ph.D.\*  
Mark D. Moore, Ph.D.\*  
Louis H. Iselin, Ph.D.\*  
Raymund F. Eich, Ph.D.\*  
Bradley A. Misley\*  
Thomas H. Belvin, Jr.\*

\*Patent Agent

WRITER'S DIRECT DIAL:  
(713) 934-4079

March 20, 2001

FILE: 4001.002282

CERTIFICATE OF MAILING 37 C.F.R. § 1.8	
I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:	
March 20, 2001	
Date	Shelley P.M. Fussey

Assistant Commissioner for Patents  
Washington, DC 20231

RE: *U.S. Patent Application Serial No. 09/351,862; Entitled "Cancer Treatment Kits Using Antibodies to Aminophospholipids"; Inventors: Thorpe and Ran; Client Reference: UTSMC/DAL:549--1*

Sir:

Enclosed for filing in the above-referenced patent application is:

- (1) A Supplemental Information Disclosure Statement, PTO Form 1449 and copy of Reference A21; and
- (2) A postcard listing these materials; please date stamp and return the postcard evidencing receipt of these materials.

WILLIAMS, MORGAN & AMERSON, P.C.

Assistant Commissioner for Patents

March 20, 2001

Page 2

No fees are believed to be due in connection with the filing of these materials, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason, the Assistant Commissioner is hereby authorized to deduct said fees from Williams, Morgan & Amerson, P.C. Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,



Shelley P.M. Fussey, Ph.D.

Reg. No. 39,458

Patent Agent

Encls.



CERTIFICATE OF MAILING  
37 C.F.R. § 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date below:

March 20, 2001

Date

  
Shelley M. Fussey

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Philip E. Thorpe and Sophia Ran

Serial No.: 09/351,862

Filed: July 12, 1999

For: CANCER TREATMENT KITS USING  
ANTIBODIES TO  
AMINOPHOSPHOLIPIDS

Group Art Unit: 1642

Examiner: Sharareh, S.

Atty. Dkt. No.: 4001.002282

RECEIVED

MAR 26 2001

TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Supplemental Information Disclosure Statement be entered and the document listed on attached Form PTO-1449 be considered by the Examiner and made of record in the present case. A copy of the listed document required by 37 C.F.R. § 1.98(a)(2) is enclosed for the convenience of the Examiner.

In accordance with 37 C.F.R. §§ 1.97(g),(h), this Supplemental Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The present Supplemental Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is timely filed in accordance with 37 C.F.R. § 1.97(b). Therefore, no fees should be due in connection herewith. Even if an Official Action had issued in the last few days, no fee would still be due to formally enter the listed document into the record in light of the following certification.

In accordance with 37 C.F.R. § 1.97(e)(2), Applicants undersigned representative hereby certifies that the item of information contained in this Supplemental Information Disclosure Statement was not cited in a communication from a foreign patent office in a counterpart foreign application. The listed document was cited in an Official Action on the merits in co-pending application Serial No. 09/351,149 (Attorney Docket No. 3999.002383) mailed from the P.T.O. on March 13, 2001, less than three months before the filing of the present statement, and evidently could not have been submitted before receipt. The present Supplemental Information Disclosure Statement would thus be timely filed in accordance with 37 C.F.R. § 1.97(c).

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Examiner should contact the undersigned representative to discuss deduction from Williams, Morgan & Amerson Deposit Account No. 50-0786/4001.002282.

Respectfully submitted,



Shelley P.M. Fussey  
Reg. No. 39,458  
Agent for Applicant

WILLIAMS, MORGAN & AMERSON, P.C.  
7676 Hillmont, Suite 250  
Houston, Texas, 77040  
(713) 934-4079

Date: March 20, 2001